Cardiac amyloidosis: A report of two cases  by Munjewar, Chandrashekhar et al.
ww.sciencedirect.com
i n d i a n h e a r t j o u rn a l 6 6 ( 2 0 1 4 ) 4 7 3e4 7 6Available online at wScienceDirect
journal homepage: www.elsevier .com/locate/ ih jCase ReportCardiac amyloidosis: A report of two casesChandrashekhar Munjewar a,*, Rahul Agrawal a, Satyavan Sharma b
a Registrar, Department of Cardiology, Bombay Hospital Institute of Medical Sciences, New Marine Lines,
Mumbai 400020, Maharashtra, India
b Professor and Head, Department of Cardiology, Bombay Hospital Institute of Medical Sciences, New Marine Lines,
Mumbai 400020, Maharashtra, Indiaa r t i c l e i n f o
Article history:
Received 12 June 2013
Accepted 24 May 2014
Available online 24 June 2014
Keywords:
Cardiac amyloidosis
Waldenstrom's macroglobulinemia
Plasma cell dyscrasia* Corresponding author.
E-mail address: cbmunjewar@yahoo.co.in
http://dx.doi.org/10.1016/j.ihj.2014.05.028
0019-4832/Copyright © 2014, Cardiological Sa b s t r a c t
Cardiac amyloidosis is a manifestation of multisystem disorder. The condition is rare,
difficult to diagnose and invariably fatal. We report 2 cases of amyloidosis associated with
plasma cell dyscrasia. A high index of clinical suspicion, echocardiographic clues (ven-
tricular thickening, diastolic dysfunction, biatrial enlargement) and elevated cardiac bio-
markers led to the diagnosis. Early institution of amyloid specific treatment should be the
aim. Cardiac treatment is supportive and results are often disappointing.
Copyright © 2014, Cardiological Society of India. All rights reserved.1. Introduction
Systemic amyloidosis is a relatively raremultisystem disorder
caused by extracellular deposits of insoluble fibril proteins in
various tissues and organs. Amyloidosis patients may present
to any speciality and the diagnosis is frequently delayed.
Cardiac amyloidosis refers to involvement of the heart by
amyloid deposition whether as a part of systemic amyloidosis
(as is most commonly the case) or as a localized
phenomenon.1,2
We report two cases of this rare disease associated with
Waldenstrom's macroglobulinemia in one and uncertain type
of plasma cell dyscrasia in the other. The cases highlight the
difficulties in recognition and adverse prognosis. Role of
echocardiography, cardiac biomarkers and tissue biopsy in
diagnosis is emphasized.(C. Munjewar).
ociety of India. All rights2. Case reports
2.1. Case I
A 22 years young male was referred in 2008 with progressive
dyspnea, fatigue and episodes of presyncope during the last 6
months. He gave history of receiving antitubercular therapy
six months back for a febrile illness and attributed all his
symptoms to this therapy.
Clinical examination revealed anemia, blood pressure of
90/70 mmHg, slow atrial fibrillation (AF), elevated jugular
venous pressure, cardiomegaly, loud P2, hepatomegaly and
clear lung fields. Relevant blood investigations revealed ane-
mia, mildly deranged liver and renal function tests attribut-
able to heart failure. Cardiac troponin (2.35 ng/ml, normal
<0.1 ng/ml) and NT pro BNP (1600 pg/ml, normal <125 pg/ml)reserved.
i n d i a n h e a r t j o u r n a l 6 6 ( 2 0 1 4 ) 4 7 3e4 7 6474were elevated. Electrocardiogram revealedAFwith ventricular
rate of 30e35beats/minute and non-specific ST-T changes.
Skiagram of chest revealed cardiomegaly (cardiothoracic ratio
of 0.65), prominent left and right atrium and signs of pulmo-
nary venous hypertension. Two dimensional echocardiogra-
phy (Fig. 1A and B) revealed marked thickening and speckled
appearance of interventricular septum, left ventricular and
right ventricular posterior wall, biatrial dilatation and left
ventricular ejection fraction (LVEF) of 70%. Atrioventricular
valveswere normal. Doppler interrogation revealed restrictive
pattern and moderate pulmonary hypertension (PH). Hemo-
dynamic data is shown in Table 1 and revealed elevation of
end diastolic pressure in both the ventricles andmoderate PH.
Left and right ventriculography (Fig. 1C and D) showed hy-
pertrophy of the ventricles, delayed relaxation, normal sys-
tolic function and favored a cardiac infiltrative disease.
Abdominal fat pad biopsy demonstrated apple green bire-
fringence on staining with Congo red and provided the diag-
nosis of amyloidosis. Serum and urine electrophoresis and
bone marrow suggested abnormal plasma cells. Serum
immunofixation test could not be performed. There was
marginal symptomatic benefit with diuretics and a VVI pace-
maker implantation. No specific therapy for amyloidosis was
initiated. Six months later, patient died at home.
2.2. Case II
A 72 years male with Waldenstrom's macroglobulinemia, was
admitted to hematology unit of our institute for chemo-
therapy in September 2012. He had cough, dyspnea and anFig. 1 e Two dimensional echocardiography in short axis (A) and
thickening of interventricular septum, LV and RV posterior wal
hypertrophied ventricles. LA e left atrium, RA e right atrium, Lepisode of transient AF. Skiagram chest PA view revealed
bilateral basal haziness and computed tomography (CT) of
chest showed minimal bilateral pleural effusion and intersti-
tial septal thickening. Bronchoscopy did not reveal any ab-
normality. Serial electrocardiograms showed sinus rhythm
and non-specific ST-T changes. Bedside two dimensional
echocardiography revealed normal cardiac valves, normal
LVEF, no pericardial effusion and no PH. Chemotherapy using
monoclonal antibody rituximab, steroids and supportive
treatment was instituted. There was partial response and
patient returned to his hometown.
A month later, he was readmitted with altered sensorium
and progressive dyspnea. Clinical assessment revealed
tachypnea, irregular pulse, blood pressure of 100/70 mmHg,
bilateral basal crepts and no murmur or S3 gallop. Serial
electrocardiograms during the next one week revealed vary-
ing rhythms (AF, atrioventricular dissociation, bradyar-
rhythmias and non-specific ST-T changes). Serial skiagrams
of chest revealed hilar haziness, signs of pulmonary venous
congestion and suggested pulmonary edema. Relevant blood
investigations revealed anemia (Hbe 9.5 g%, normale 13e17 g
%), hyponatremia (Serum Na e 113 mEq/L, normal e
137e150 mEq/L), markedly elevated NT Pro BNP (5606 pg/ml,
normal <125 pg/ml). Other biochemistry tests were normal.
Repeat two dimensional echocardiography revealed
massively thickened interatrial septum (39 mm, normal e
6 ± 2mm) and thickening of left and right ventricular posterior
wall (Fig. 2A and B). There was biatrial dilatation, normal
cardiac valves and LVEF of 60%. Doppler interrogation
revealed evidence of diastolic dysfunction (E/E0 e 39).apical 4 chamber view (B) shows speckled appearance and
l. LV angiogram (C) and RV angiogram (D) showing
V e left ventricle, RV e right ventricle.
Table 1 e Hemodynamic data (Case I).
Chamber Pressure (mmHg)
RA m e 18
RV 70/18
MPA 70/30, m e 40
Ao 100/70, m e 82
LV Systolic e100, LVEnDP e20, LVEaDP e8
Abbreviations: RA e right atrium, RV e right ventricle, m e mean,
MPA e main pulmonary artery, Ao e aorta, LV e left ventricle,
LVEnDP e LV end diastolic pressure, LVEaDP e LV early diastolic
pressure.
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eosinophilic material demonstrating apple green birefrin-
gence under polarized light, characteristic of amyloid (Fig. 2C
and D). Despite intensive chemotherapy using alkylating
agent melphalan, immunomodulator lenalidomide and ste-
roids, patient continued to deteriorate and died at home after
6 weeks.3. Discussion
Amyloidosis is a clinical disorder caused by extracellular and/
or intracellular deposition of insoluble abnormal amyloid fi-
brils that alter the normal function of tissues. Amyloidosis
used to be classified as primary when no associated illness
was identified and secondary when chronic inflammatory
conditions coexisted.3,4 The current classification is based on
the type of fibril protein. More than 30 proteins are known to
be able to form amyloid fibril in vivo, which cause disease byFig. 2 e Two dimensional echocardiography showing LV/RV pos
septal thickening in apical 5 chamber view (B). Abdominal fat p
deposit under light microscopy (C) and green-apple birefringencprogressively damaging the structure and function of affected
tissue. The various types of amyloid described include AL
amyloidosis (previously referred to as primary amyloidosis),
AA amyloidosis (earlier known as secondary amyloidosis),
transthyretin amyloidosis and various others. AA amyloid
rarely affects the heart.3,4
Both the patients possibly had AL amyloidosis. AL
amyloidosis is caused by deposition of fibrils composed of
monoclonal immunoglobulin light chain and is associated
with clonal plasma cells or other B cell dyscrasias.2 The
spectrum and pattern of organ involvement is very wide but
cardiac involvement occurs in half the cases and is sometimes
the only presenting feature. The first case had predominantly
cardiac involvement and had a rapidly fatal outcome. The
second patient in this report had Waldenstrom's macroglob-
ulinemia, well known to be associated with AL amyloidosis.
Cardiac amyloidosis irrespective of the type, presents as
restrictive cardiomyopathy characterized by progressive dia-
stolic and subsequently systolic biventricular dysfunction and
arrhythmia. Both the patients presented with features of
restrictive cardiomyopathy and had AF. Measurements of NT
Pro BNP troponins can be extremely useful in diagnosis and
assessment of prognosis of AL amyloidosis.5 In second patient
elevated NT Pro BNP drew our attention to cardiac involve-
ment. BNP/NT Pro BNP in general reflects high filling pres-
sures, but amyloid deposits may have a local effect. Increase
troponins are a marker of poor prognosis but the mechanism
remains unclear.
Echocardiography plays a pivotal role in diagnosis and
shows several features that can be suggestive of cardiac
amyloidosis.2e4 However it is important to recognize that
characteristic features are commonly present only in the laterterior wall thickening in short axis view (A) and interatrial
ad biopsy with Congo red stain showing amorphous pink
e under polarized microscopy (D). Abbreviations as in Fig. 1.
i n d i a n h e a r t j o u r n a l 6 6 ( 2 0 1 4 ) 4 7 3e4 7 6476stages of the disease. In case II, diagnostic features could be
seen only during follow up echocardiograms when patient
had advanced disease. The most common echocardiographic
feature is thickening of the left ventricular wall. This feature
has a poor specificity for amyloidosis because of its occur-
rence with other conditions such as hypertensive heart dis-
ease, hypertrophic cardiomyopathy and other infiltrative
diseases.4 A speckled or granular myocardial (sparkling)
appearance (as in case I) has been reported to be characteristic
of amyloidosis. However this finding should be interpreted
within the clinical context as this finding is dependent on
machine gain settings and can also occur in other causes of LV
hypertrophy. A thickened interatrial septum (as in Case II) is
very specific for amyloid in the later stage of the disease, with
100% specificity.6 Other features of cardiac amyloid include
bilaterally enlarged atria (seen in both cases), thickened valves
and pericardial effusion. Diastolic dysfunction is the hallmark
and majority of patients show a restrictive pattern on mitral
inflow assessment. Advanced echocardiographic techniques
with speckle tracking can be of great use in diagnosis.7
Cardiacmagnetic resonance (CMR) provides functional and
morphological information similar to echocardiography. An
advantage of CMR is tissue characterization. Both the patients
were quite sick, had arrhythmias and it was unlikely that CMR
would have provided any additional information. Endomyo-
cardial biopsy has been considered to be gold standard for
demonstrating cardiac amyloid deposition.2 In clinical prac-
tice it is rarely necessary to biopsy the heart if clinical, echo-
cardiographic and biochemical information is sufficient for
diagnosis and a histopathological data is available from other
tissues as in both the cases. Cardiac amyloidosis has a poor
prognosis8 and both patients died within a short period.
Treatment may be classified as supportive (i.e. heart failure
therapy) and therapies that suppress production of respective
amyloid fibril precursor protein (eg. chemotherapy in AL
amyloidosis). Standard heart failure therapymay be of limited
benefit or even detrimental due to low blood pressure andarrhythmias. Pacemakers and other devices also provide little
benefit. Several specific newer drugs directed at reducing
amyloid fibril precursor protein production are currently
available and can be used.2 The cases are reported due to the
rarity.Conflicts of interest
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